Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11819554

Compositions and methods for modulating FMR1 expression

Fulcrum Therapeutics, Inc. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11807661

Antibody fusion protein and related compositions for targeting cancer

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806318

Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflamma

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11790574

System and method for carbon dioxide angiographic roadmap imaging

GE Precision Healthcare LLC · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11788141

MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK ce

Precision for Medicine GmbH · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11788077

Polynucleotides encoding optimized engineered meganucleases having specificity for a recog

Precision BioSciences, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786554

Optimized engineered nucleases having specificity for the human T cell receptor alpha cons

Precision BioSciences, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11781143

Modulators of PNPLA3 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771723

Bifidobacterium longum NCIMB 41676

PrecisionBiotics Group Limited · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11767367

Monoclonal antibody neo-201 for the treatment of human carcinomas

PRECISION BIOLOGICS, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11767325

Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

PRAXIS PRECISION MEDICINES, INC. · Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11761003

Adeno-associated virus for activating RNA-NEAT1 over-expression and applications thereof

EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753644

Compounds and methods for reducing IFNAR1 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753630

Polynucleotides encoding engineered meganucleases having specificity for recognition seque

Precision BioSciences, Inc. · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11753408

Compounds and method for blocking transmission of malarial parasite

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11744800

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11731966

Compounds and their methods of use

PRAXIS PRECISION MEDICINES, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11731976

3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazol

PRAXIS PRECISION MEDICINES, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11731978

3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazol

PRAXIS PRECISION MEDICINES, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11732265

Compositions and methods for modulating complement factor B expression

Ionis Pharmaceuticals, Inc. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730793

Sustained release formulations using non-aqueous emulsions

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11723885

Methods and compositions for interfering with extraction or conversion of a drug susceptib

Acurx Pharmaceuticals, Inc. · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11723946

Methods for regulating transcription of multiple genes and expression of multiple targets

China Medical University · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713462

Modulation of GYS1 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted